Avinger (NASDAQ:AVGR) Earns Buy Rating from Analysts at Aegis

Share on StockTwits

Research analysts at Aegis initiated coverage on shares of Avinger (NASDAQ:AVGR) in a research report issued to clients and investors on Thursday, The Fly reports. The brokerage set a “buy” rating on the medical device company’s stock.

Other research analysts also recently issued research reports about the stock. Zacks Investment Research upgraded shares of Avinger from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a research note on Tuesday, August 6th. ValuEngine downgraded shares of Avinger from a “buy” rating to a “hold” rating in a research note on Wednesday, September 4th.

Shares of NASDAQ AVGR traded up $0.02 during midday trading on Thursday, hitting $1.16. The company’s stock had a trading volume of 51,860 shares, compared to its average volume of 386,809. The business’s fifty day simple moving average is $1.55 and its two-hundred day simple moving average is $1.19. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.45 and a quick ratio of 1.17. Avinger has a 1 year low of $1.04 and a 1 year high of $15.90. The firm has a market capitalization of $7.20 million, a price-to-earnings ratio of -0.03 and a beta of 1.58.

Avinger (NASDAQ:AVGR) last issued its quarterly earnings results on Wednesday, July 31st. The medical device company reported ($0.87) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.03. Avinger had a negative net margin of 258.12% and a negative return on equity of 230.13%. The company had revenue of $2.32 million during the quarter. Analysts anticipate that Avinger will post -2.61 EPS for the current fiscal year.

An institutional investor recently bought a new position in Avinger stock. Spark Investment Management LLC acquired a new position in shares of Avinger Inc (NASDAQ:AVGR) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 103,043 shares of the medical device company’s stock, valued at approximately $98,000. Spark Investment Management LLC owned approximately 0.21% of Avinger at the end of the most recent quarter. 7.51% of the stock is owned by institutional investors and hedge funds.

Avinger Company Profile

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.

Recommended Story: What are trading strategies for the 52-week high/low?

The Fly

Receive News & Ratings for Avinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avinger and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Northland Securities Reiterates Hold Rating for Green Dot
Northland Securities Reiterates Hold Rating for Green Dot
Mastercard  Earns “Outperform” Rating from William Blair
Mastercard Earns “Outperform” Rating from William Blair
Huntington Bancshares  Rating Lowered to Neutral at DA Davidson
Huntington Bancshares Rating Lowered to Neutral at DA Davidson
Raymond James Upgrades M.D.C.  to “Strong-Buy”
Raymond James Upgrades M.D.C. to “Strong-Buy”
Federal Realty Investment Trust  Raised to Buy at Mizuho
Federal Realty Investment Trust Raised to Buy at Mizuho
Shiloh Industries  Lifted to “Neutral” at Bank of America
Shiloh Industries Lifted to “Neutral” at Bank of America


© 2006-2019 Ticker Report